Polaryx Therapeutics (PLYX) Q1 2026 earnings summary

Executive summary

• Clinical-stage biotech focused on therapies for rare pediatric lysosomal storage disorders (LSDs), advancing a pipeline including small molecule and gene therapies targeting unmet needs in LSDs.

• Lead candidate PLX-200 is entering a Phase 2 proof-of-concept basket trial (SOTERIA) in the second half of 2026, with potential for expedited FDA approval in certain indications.

• No products approved or revenue from product sales; operations funded primarily through equity issuances totaling $21.7 million to date.

Financial highlights

• Net loss for Q1 2026 was $2.5 million, a significant improvement from $5.1 million in Q1 2025, mainly due to a one-time $4.3 million stock-based compensation expense in 2025.

• Research and development expenses decreased to $679 thousand from $4.7 million year-over-year, reflecting the absence of the prior year’s non-recurring stock-based compensation.

• General and administrative expenses rose to $1.3 million from $336 thousand, driven by public company costs and increased stock-based compensation.

• Cash and cash equivalents were $3.1 million as of March 31, 2026, down from $5.1 million at year-end 2025.

• No revenue recognized; full valuation allowance maintained on deferred tax assets.

Outlook and guidance

• Existing cash is expected to fund operations through Q3 2026; additional capital will be required beyond that period.

• Management anticipates continued operating losses and negative cash flows as clinical and preclinical programs advance.

• Future funding needs depend on clinical progress, regulatory milestones, and potential commercialization activities.